Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial

APPRAISE Steering Committee and Investigators; John H Alexander; Richard C Becker; Deepak L Bhatt; Frank Cools; Filippo Crea; Mikael Dellborg; Keith A A Fox; Shaun G Goodman; Robert A Harrington; Kurt Huber; Steen Husted; Basil S Lewis; Jose Lopez-Sendon; Puneet Mohan; Gilles Montalescot; Mikhail Ruda; Witold Ruzyllo; Freek Verheugt; Lars Wallentin

doi:10.1161/CIRCULATIONAHA.108.832139

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial

APPRAISE Steering Committee and Investigators, John H Alexander, Richard C Becker, Deepak L Bhatt, Frank Cools, Filippo Crea, Mikael Dellborg, Keith A A Fox, Shaun G Goodman, Robert A Harrington, Kurt Huber, Steen Husted, Basil S Lewis, Jose Lopez-Sendon, Puneet Mohan, Gilles Montalescot, Mikhail Ruda, Witold Ruzyllo, Freek Verheugt, Lars Wallentin

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding.

Original language	English
Pages (from-to)	2877-85
Number of pages	9
Journal	Circulation
Volume	119
Issue number	22
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.108.832139
Publication status	Published - Jun 2009

Access to Document

10.1161/CIRCULATIONAHA.108.832139

Fingerprint

Dive into the research topics of 'Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial'. Together they form a unique fingerprint.

Cite this

APPRAISE Steering Committee and Investigators, Alexander, J. H., Becker, R. C., Bhatt, D. L., Cools, F., Crea, F., Dellborg, M., Fox, K. A. A., Goodman, S. G., Harrington, R. A., Huber, K., Husted, S., Lewis, B. S., Lopez-Sendon, J., Mohan, P., Montalescot, G., Ruda, M., Ruzyllo, W., Verheugt, F., & Wallentin, L. (2009). Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation, 119(22), 2877-85. https://doi.org/10.1161/CIRCULATIONAHA.108.832139

APPRAISE Steering Committee and Investigators ; Alexander, John H ; Becker, Richard C et al. / Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome : results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. In: Circulation. 2009 ; Vol. 119, No. 22. pp. 2877-85.

@article{3170824f3de24012b8eb64d3acb65ed7,

title = "Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial",

abstract = "After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding.",

author = "{APPRAISE Steering Committee and Investigators} and Alexander, {John H} and Becker, {Richard C} and Bhatt, {Deepak L} and Frank Cools and Filippo Crea and Mikael Dellborg and Fox, {Keith A A} and Goodman, {Shaun G} and Harrington, {Robert A} and Kurt Huber and Steen Husted and Lewis, {Basil S} and Jose Lopez-Sendon and Puneet Mohan and Gilles Montalescot and Mikhail Ruda and Witold Ruzyllo and Freek Verheugt and Lars Wallentin",

year = "2009",

month = jun,

doi = "10.1161/CIRCULATIONAHA.108.832139",

language = "English",

volume = "119",

pages = "2877--85",

journal = "Circulation",

issn = "0009-7322",

publisher = "AMER HEART ASSOC",

number = "22",

}

APPRAISE Steering Committee and Investigators, Alexander, JH, Becker, RC, Bhatt, DL, Cools, F, Crea, F, Dellborg, M, Fox, KAA, Goodman, SG, Harrington, RA, Huber, K, Husted, S, Lewis, BS, Lopez-Sendon, J, Mohan, P, Montalescot, G, Ruda, M, Ruzyllo, W, Verheugt, F & Wallentin, L 2009, 'Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial', Circulation, vol. 119, no. 22, pp. 2877-85. https://doi.org/10.1161/CIRCULATIONAHA.108.832139

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. / APPRAISE Steering Committee and Investigators; Alexander, John H; Becker, Richard C et al.
In: Circulation, Vol. 119, No. 22, 06.2009, p. 2877-85.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome

T2 - results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial

AU - APPRAISE Steering Committee and Investigators

AU - Alexander, John H

AU - Becker, Richard C

AU - Bhatt, Deepak L

AU - Cools, Frank

AU - Crea, Filippo

AU - Dellborg, Mikael

AU - Fox, Keith A A

AU - Goodman, Shaun G

AU - Harrington, Robert A

AU - Huber, Kurt

AU - Husted, Steen

AU - Lewis, Basil S

AU - Lopez-Sendon, Jose

AU - Mohan, Puneet

AU - Montalescot, Gilles

AU - Ruda, Mikhail

AU - Ruzyllo, Witold

AU - Verheugt, Freek

AU - Wallentin, Lars

PY - 2009/6

Y1 - 2009/6

N2 - After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding.

AB - After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding.

U2 - 10.1161/CIRCULATIONAHA.108.832139

DO - 10.1161/CIRCULATIONAHA.108.832139

M3 - Article

C2 - 19470889

SN - 0009-7322

VL - 119

SP - 2877

EP - 2885

JO - Circulation

JF - Circulation

IS - 22

ER -

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139